Thursday, 19 April 2018 - 10:32
  • it
  • de
  • en
  • fr

AstraZeneca

Ionis sells NASH therapy to AstraZeneca for $300m

California-based Ionis Pharmaceuticals has announced it has licensed to AstraZeneca its investigational therapy Ionis-AZ6-2.5, developed to treat patients with Non-Alcoholic Steatohepatitis (NASH). This is the third therapy obtained from the partnership between the firms. Under the terms of the agreement,…

Ups and downs in AstraZeneca’s annual results

AstraZeneca has announced today its 2017 results to the financial community. Sales declined by 2% in 2017 to $22.46bn, and reported operating profit was down 25%, due to the higher costs to be born to launch new drugs. AstraZeneca’s press…

AstraZeneca’s asthma therapy approved in Europe as well

MedImmune’s (AstraZeneca) monoclonal antibody benralizumab has been approved in Europe for the treatment of severe asthma. The drug was recommended by EMA CHMP last November and was approved in the US in the same month. Benralizumab will be available as…

Vectura targeted by AstraZeneca and Novartis (GBP700m)

The Daily Telegraph has reported today that UK-based Vectura Group is targeted by AstraZeneca. According to rumors circulating yesterday, instead, Novartis–a partner of Vectura’s–is planning to acquire it completely. Vectura’s shares have lost over 21% of their value since January…

Leif Johansson, AstraZeneca’s chairman, on possible Brexit aftermaths

Leif Johansson, chairman of pharmaceutical group AstraZeneca, has addressed in an interview to Handelsblatt the aftermaths of Brexit in the pharma sector. Johansson, 66, from Sweden, MSc in mechanical engineering and former chairman of Ericsson group, has said that AstraZeneca…

Dizal Pharmaceutical, new JV created by AstraZeneca and Chinese partner

AstraZeneca has announced today it has entered into an agreement with China-based Future Industry Investment Fund (FIIF), in order to establish a joint venture named Dizal Pharmaceutical. The newly-created JV will focus on drug discovery – which is consistent with…

AstraZeneca reports third quarter results exceeding expectations

UK-based AstraZeneca today presented its Q3 results to investors and analysts. The data exceeded market expectations, thus the company’s management took the opportunity to improve the expected sales for 2017. Sales rose by 9% over Q3 2016, to $6.2bn (vs…

Significant news from AstraZeneca

AstraZeneca has reported results from the Phase III STRATOS 2 clinical trial, designed to assess tralokinumab, an anti-interleukin-13 (IL-13) monoclonal antibody in patients with uncontrolled asthma. The data show that tralokinumab does not provide any advantage on conventional therapies. Denmark-based…

AstraZeneca targeting California-based Acadia Pharmaceuticals ($4.4bn)

The English daily The Evening Standard yesterday reported that AstraZeneca is interested in acquiring the California-based Acadia Pharmaceuticals. Acadia currently has a capitalization of approximately $4.4bn (Nasdaq) and its shareholders include the Baker Brothers fund (21%). Acadia’s key asset is…

Daiichi Sankyo denies rumored offer by AstraZeneca

Japan-based Daiichi Sankyo today issued a very short press release denying it received an acquisition offer by UK-based AstraZeneca last year. The release came immediately after the Japanese weekly Nikkei Business published an article reporting negotiations between the groups in…

Impending merger rumored in Japan between AstraZeneca and Daiichi Sankyo

Japan weekly Nikkei Business today reported that UK-based AstraZeneca last year tried to acquire Japan-based Daiichi Sankyo, which has a market value exceeding $16bn. According to the article, negotiations are still underway and a merger between the groups, which would…

Long-term treatment with AstraZeneca’s Brilinta: new data

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial. The data demonstrate a 29% risk reduction in cardiovascular death from treatment with Brilinta (ticagrelor) 60mg administered twice daily, versus placebo, in patients…

AstraZeneca and Germany-based Ethris to cooperate for lung diseases

Ethris GmbH, a Germany-based company focusing on therapies using mRNA, mainly intended to address lung diseases, entered into a five-year partnership with AstraZeneca and its R&D arm MedImmune. The partners will use the SNIM®RNA technology, property of Ethris. The German…

AstraZeneca on the upturn: FDA grants Breakthrough Therapy Designation to Imfinzi

AstraZeneca and MedImmune, its global biologics research and development arm, announced that FDA granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer, whose disease has not progressed following platinum-based chemoradiation…

Pascal Soriot to remain AstraZeneca CEO

Pascal Soriot won’t leave AstraZeneca. The news was indirectly confirmed by the Britain-based company, as it informed that the French manager will announce the Q2 2017 results on July 27. The news puts an end to two days of speculations…

Pascal Soriot about to leave AstraZeneca to become Teva CEO

Reuters reported yesterday, in the late evening, that Pascal Soriot, 58, current AstraZeneca CEO, is about to leave the UK-based group and to become CEO of Israel-based TEVA Pharmaceuticals. The news started circulating in the morning, when the Tel Aviv-based…

Joerg Reinhardt, Novartis chairman, addresses Alcon, Roche and M&A plans

Swiss Economic-financial biweekly Finanz und Wirtschafts today published a long interview to Novartis chairman Joerg Reinhardt, who said that the Basel-based group will keep focusing small-scale acquisitions. Reinhardt, however, said he wouldn’t mind approving a major >CHF10bn acquisition, provided that…

AstraZeneca takes a gamble

When AstraZeneca’s board, led by CEO Pascal Soriot, rejected Pfizer’s $69bn takeover attempt, it promised investors that the group would become the leader of oncological industry and its revenues would reach $45bn pa by 2023. Soriot took a gamble, which…

AstraZeneca sells Zomig to Grünenthal for $302m

UK-based pharmaceutical group AstraZeneca sold commercialization rights to Zomig, a treatment of migraines and cluster headaches to Germany’s Grünenthal for $302m. Specifically, under the agreement, Zomig will market the product in all markets outside Japan, including the US, where Zomig…

What future for immuno-oncology?

On the eve of the American Society of Clinical Oncology annual meeting, pharmaceutical industry analysts are wondering what is the future of immuno-oncology. Few treatment areas, indeed, have seen so many changes and innovations as oncology over such a short…